Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-01-30
2009-08-11
Saeed, Kamal A (Department: 4121)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S262200, C548S266800
Reexamination Certificate
active
07572822
ABSTRACT:
Biaryl substituted triazole compounds represented by Formula I, II or III, or pharmaceutically acceptable salts thereof, and a process for making such compounds and salts thereof. Pharmaceutical compositions comprise an effective amount of the instant compounds, either alone, or in combination with one or more other therapeutically active compounds, and a pharmaceutically acceptable carrier. Methods of treating conditions associated with, or caused by, sodium channel activity, including, for example, acute pain, chronic pain, visceral pain, inflammatory pain, neuropathic pain, epilepsy, irritable bowel syndrome, depression, anxiety, multiple sclerosis, and bipolar disorder, comprise administering an effective amount of the present compounds, either alone, or in combination with one or more other therapeutically active compounds. A method of administering local anesthesia comprises administering an effective amount of a compound of the instant invention, either alone, or in combination with one or more other therapeutically active compounds, and a pharmaceutically acceptable carrier.
REFERENCES:
patent: 6849636 (2005-02-01), Waddell et al.
patent: 6875782 (2005-04-01), Cheng et al.
patent: 6962936 (2005-11-01), Hale et al.
patent: RE38962 (2006-01-01), Rossi
patent: 7019144 (2006-03-01), Cho et al.
patent: 7326726 (2008-02-01), Chakravarty et al.
patent: 7459475 (2008-12-01), Park et al.
patent: 0572 142 (1993-05-01), None
patent: WO 94/22852 (1994-10-01), None
patent: WO 99/32462 (1999-07-01), None
patent: WO 00/57877 (2000-10-01), None
patent: WO 01/68612 (2001-09-01), None
Patani, et al. Bioisosterism: A Rational Approach in Drug Design, Chem. Rev. 1996, 96, pp. 3147-3176, especially p. 3149.
Omodei-Sale et al. J. Med. Chem. 26 (8), 1983.
J. J. Clare et al., “Voltage-Gated Sodium Channels as Therapeutic Targets”, 2000, vol. 5, pp. 506-520, Therapeutic Forces.
W. A. Catterall, “Structure and Function of Voltage-Gated Sodium and Calcium Channels”, 1991, vol. 1, pp. 5-13, Current Opinion in Neurobiology.
M. D. Baker et al., “Involvement of Na+ Channels in Pain Pathways”, 2001, vol. 22, No. 1, pp. 27-31, Trends in Pharmacological Sciences.
J. Mao et al., “Systemic Lidocaine for Neuropathic Pain Relief”, 2000, vol. 87, pp. 7-17, Pain.
D. L. Tanellian et al., “Neuropathic Pain Can be Relieved by Drugs That Are Use-dependent Sodium Channel Blockers: Lidocaine, Carbamazepine, and Mexiletine”, vol. 74, pp. 949-951, Anesthesiology.
T. Anger et al., “Medicinal Chemistry of Neuronal Voltage-Gated Sodium Channel Blockers”, 2001, vol. 44, No. 2, pp. 115-137, J. Med. Chem.
A. Devers et al., “Topical Lidocaine Patch Relieves a Variety of Neuropathic Pain Conditions: An Open-Label Study”, 2000, vol. 16, pp. 205-208, The Clinical Journal of Pain.
J. March et al., “Reactions, Mechanisms, and Structure”, 2001, pp. 506-512, March's Advanced Organic Chemistry, Fifth Edition.
A. Suzuki et al., “Palladium-Catalyzed Cross-Coupling Reactions of Organoboron Compounds”, 1995, vol. 7, pp. 2457-2483, Chemical Reviews.
J. J. Li et al., “1,2-Diarylcyclopentenes as Selective Cyclooxygenase-2 Inhibitors and Orally Active Anti-Infammatory Agents”, 1995, vol. 38, pp. 4570-4578, J. of Medicinal Chemistry.
S. R. Piettre et al., “Monoaryl-and Bisaryldihydroxytropolones as Potent Inhibitors of Inositol Monophosphatase”, 1997, vol. 40, pp. 4208-4221, J. of Medicinal Chemistry.
A. Giroux et al., “One Pot Biaryl Synthesis Via in Situ Boronate Formation”, 1997, vol. 38, No. 22 pp. 3841-3844, Tetrahedron Letters.
M. Murata et al., “Palladium-Catalyzed Borylation of Aryl Halides or Triflates with Dialkoxyborane: A Novel and Facile Synthetic Route to Arylboronates”, 2000, vol. 65, pp. 164-168, J. Org. Chem.
Y. Lin et al., “New Synthesis of 1,2, 4-Triazoles and 1,2,4-Oxadiazoles”, 1979, vol. 44, pp. 4160-4164, J. of Organic Chemistry.
G. T. Carter et al., “Advances in the Management of Neuropathic Pain”, 2001, vol. 12, pp. 447-459, Pysical Medicine and Rehabilitation Clinics of North America.
Chemical Abstracts, vol. 78, 1973, p. 464, Abstract No. 72013w.
A. Omodei-Sale et al., “A New Class of Nonhormonal Pregancy-Terminating Agents. Synthesis and Contragestational Activity of 3,5- Diaryl-s-Triazoles”, 1983, vol. 26, pp. 1187-1192, American Chemical Society.
G. A. Patani et al., “Bioisosterism: A Rational Approach in Drug Design”, 1996, vol. 96, pp. 3147-3176, Chem. Rev.
D. Catarzi et al, “Synthesis of Some 2-Aryl-1,2 4-Triazolo[1,5-c][1,3] Benzoxazin-5-Ones as Tools to Define the Essential Pharmacophoric Descriptors of a Benzodiazepine Receptor Ligand”, 1995, vol. 38, No. 12, pp. 2196-2201, J. of Medicinal Chemistry.
J. E. Baldwin et al., “Concise Syntheses of acromelic Acid A and Ilo-Acromelic Acid A”, 1998, vol. 39, pp. 707-710, Tetrahedron Letters.
Chakravarty Prasun K.
Palucki Brenda
Park Min K.
Parsons William H.
Zhou Bishan
Ayler Sylvia A.
Fierro Alicia L
Krovatin William
Merck & Co. , Inc.
Saeed Kamal A
LandOfFree
Biaryl substituted triazoles as sodium channel blockers does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Biaryl substituted triazoles as sodium channel blockers, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Biaryl substituted triazoles as sodium channel blockers will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4087709